Optimizing & Validating 3D Vascularized Tissue Models & Organ‑on‑Chip Platforms for Oncology Drug Screening
- Showcasing the development and optimization of physiologically relevant, vascularized tumor models across bioprinted tissues and organ on chip systems, enabling controlled and reproducible cancer-endothelium interactions that recapitulate key features of the tumor microenvironment
- Demonstrating robust model validation using high content imaging and assays to generate quantitative readouts of tumor growth, invasion, and pharmacological responses, ensuring biological relevance, reproducibility, and scalability for translational research applications
- Highlighting how these platforms support mid throughput drug screening, transcriptomics guided target prioritization, and functional genomics approaches to uncover drivers of tumor aggressiveness, epithelial–mesenchymal transition (EMT), and context dependent drug responses, thereby informing mechanism based therapeutic development